0.33 USD
▲+0.02+5.67%
盘后 0.31 -0.06%
2026-08-03
市值
$11.76M
市盈率
—
EPS
-2.96
股息率
—
52 周区间
0.26 – 1.89
成交量
424.67K
Beta
0.84
目标价
—
52W 低 0.2652W 高 1.89
价格走势
公司简介
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product cand...